The North Shore University Hospital CCOP has developed a multidisciplinary approach to cancer treatment utilizing the expertise of full-time and private practice medical oncologists, pediatric oncologists, radiation therapists, surgeons, administrative, and support care staff. Cancer treatment and cancer control protocols will continue to be supplied by research bases to provide state of the art treatment for patients. The NSUH CCOP will consist of two sections: 1) adult medical oncology and 2) pediatric oncology. A steering committee composed of members of the major disciplines will oversee the administration, performance, and quality of the CCOP. The research bases include Cancer & Leukemia Group B, Memorial- Sloan Kettering Cancer Center, RAdiation Therapy Oncology Group, and Children's Cancer Study Group. The participating physicians have extensive experience in clinical trials. An intense effort has already begun to fully implement a cancer control program directed by an associate principal investigator who is nationally recognized in this field. Cancer Control protocols will not only be received from the research bases but will also be authored by members of the NSDHU CCOP. Major efforts are planned for increased participation in areas such as smoking cessation, chemoprevention, cancer screening, molecular biology and supportive care. Multiple affiliations with Long Island, Metropolitan New York City, Westchester, and Connecticut hospitals and health care agencies currently exists to insure that appropriate populations of patients, including minority groups, are available for cancer control protocols. The NSUH CCOP will build on previous success in which accrual increased from 68 patient credits in year 1 to 224.6 credits in year 5. Beside diagnostic and therapeutic accomplishments, leadership in the education of physicians, medical personnel, and the community will be stressed. As a result of this effort, a strong community cancer network has been developed which closely links the NCI, research bases, physicians, and patients. The ultimate goal of the NSUH CCOP will be to provide optimal care for oncology patients in their own home environment and ultimately reduce mortality and morbidity from this disease through increased accrual to both cancer treatment and cancer control clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035279-08
Application #
3557703
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-01
Project End
1995-05-31
Budget Start
1991-06-24
Budget End
1992-05-31
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
North Shore University Hospital
Department
Type
DUNS #
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38

Showing the most recent 10 out of 111 publications